Literature DB >> 20381658

Importance of measuring glycosylated hemoglobin in patients with myocardial infarction and known diabetes mellitus.

Joshua M Stolker1, Dazhong Sun, Darcy G Conaway, Philip G Jones, Frederick A Masoudi, Pamela N Peterson, Harlan M Krumholz, Mikhail Kosiborod, John A Spertus.   

Abstract

Although medical co-morbidities commonly affect clinical outcomes after acute myocardial infarction (AMI), current performance measures of AMI quality focus exclusively on the management of the AMI itself. However, patients with AMIs frequently present with other co-morbidities, such as diabetes mellitus (DM), that also warrant assessment and management. To date, the quality of DM evaluation in patients presenting with AMIs has not been described. From January 2003 to June 2004, the Prospective Registry Evaluating Myocardial Infarction Patients: Events and Recovery-Quality Improvement (PREMIER-QI) enrolled 3,953 patients with AMIs at 19 centers in the United States. The frequency of glycosylated hemoglobin (HbA(1c)) assessment, either during the hospitalization or documented in the chart from the preceding 3 months, was prospectively evaluated. Among 1,168 patients with AMIs with preexisting DM, only 47% had recent HbA(1c) levels available, with marked variability in HbA(1c) assessment among hospitals (range 7% to 81%). Among those with available HbA(1c) levels, 39% had good control (HbA(1c) <7%), 36% had suboptimal control (HbA(1c) 7% to 9%), and 25% had poor control (HbA(1c) >9%). Patients with suboptimal and poor control were more likely to have their DM treatment intensified than those without HbA(1c) assessment (for HbA(1c) 7% to 9%, rate ratio 1.38, 95% confidence interval 1.03 to 1.85; for HbA(1c) >9%, rate ratio 2.20, 95% confidence interval 1.68 to 2.88). Similarly, patients with DM who had HbA(1c) measured were more likely to receive instructions on DM disease management before discharge. In conclusion, the assessment of chronic glycemic control is highly variable among patients with AMIs and DM. Because much of this variability occurs at the hospital level, the evaluation of DM control could represent an additional quality indicator and an opportunity to advance patient-centered AMI care. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20381658      PMCID: PMC2856846          DOI: 10.1016/j.amjcard.2009.12.010

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  29 in total

1.  Intensive insulin therapy in critically ill patients.

Authors:  G van den Berghe; P Wouters; F Weekers; C Verwaest; F Bruyninckx; M Schetz; D Vlasselaers; P Ferdinande; P Lauwers; R Bouillon
Journal:  N Engl J Med       Date:  2001-11-08       Impact factor: 91.245

Review 2.  Clinical inertia.

Authors:  L S Phillips; W T Branch; C B Cook; J P Doyle; I M El-Kebbi; D L Gallina; C D Miller; D C Ziemer; C S Barnes
Journal:  Ann Intern Med       Date:  2001-11-06       Impact factor: 25.391

3.  Glycosylated hemoglobin: finally ready for prime time as a cardiovascular risk factor.

Authors:  Hertzel C Gerstein
Journal:  Ann Intern Med       Date:  2004-09-21       Impact factor: 25.391

4.  Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy. Results from the Bypass Angioplasty Revascularization Investigation (BARI).

Authors:  P B Berger; J L Velianou; H Aslanidou Vlachos; F Feit; A K Jacobs; D P Faxon; M Attubato; N Keller; M L Stadius; B H Weiner; D O Williams; K M Detre
Journal:  J Am Coll Cardiol       Date:  2001-11-01       Impact factor: 24.094

5.  Coronary bypass graft patency in patients with diabetes in the Bypass Angioplasty Revascularization Investigation (BARI).

Authors:  Leonard Schwartz; Kevin E Kip; Robert L Frye; Edwin L Alderman; Hartzell V Schaff; Katherine M Detre
Journal:  Circulation       Date:  2002-11-19       Impact factor: 29.690

Review 6.  Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview.

Authors:  S E Capes; D Hunt; K Malmberg; H C Gerstein
Journal:  Lancet       Date:  2000-03-04       Impact factor: 79.321

7.  Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes.

Authors:  Sharon H Saydah; Judith Fradkin; Catherine C Cowie
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

8.  Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association.

Authors:  Jay S Skyler; Richard Bergenstal; Robert O Bonow; John Buse; Prakash Deedwania; Edwin A M Gale; Barbara V Howard; M Sue Kirkman; Mikhail Kosiborod; Peter Reaven; Robert S Sherwin
Journal:  Circulation       Date:  2008-12-17       Impact factor: 29.690

9.  Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus.

Authors:  Ischa Stranders; Michaela Diamant; Rogier E van Gelder; Hugo J Spruijt; Jos W R Twisk; Robert J Heine; Frans C Visser
Journal:  Arch Intern Med       Date:  2004-05-10

10.  Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study.

Authors:  Anna Norhammar; Ake Tenerz; Göran Nilsson; Anders Hamsten; Suad Efendíc; Lars Rydén; Klas Malmberg
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

View more
  6 in total

Review 1.  Quality of Diabetes Care in the USA.

Authors:  Ben Alencherry; Dennis Bruemmer
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

Review 2.  Clinical significance of glycated hemoglobin in the acute phase of ST elevation myocardial infarction.

Authors:  Chiara Lazzeri; Serafina Valente; Marco Chiostri; Maria Grazia D'Alfonso; Gian Franco Gensini
Journal:  World J Cardiol       Date:  2014-04-26

3.  Association between diabetes mellitus and angina after acute myocardial infarction: analysis of the TRIUMPH prospective cohort study.

Authors:  Suzanne V Arnold; John A Spertus; Kasia J Lipska; Fengming Tang; Abhinav Goyal; Darren K McGuire; Sharon Cresci; Thomas M Maddox; Mikhail Kosiborod
Journal:  Eur J Prev Cardiol       Date:  2014-04-16       Impact factor: 7.804

4.  Relationship between glycosylated hemoglobin assessment and glucose therapy intensification in patients with diabetes hospitalized for acute myocardial infarction.

Authors:  Joshua M Stolker; John A Spertus; Darren K McGuire; Marcus Lind; Fengming Tang; Philip G Jones; Silvio E Inzucchi; Saif S Rathore; Thomas M Maddox; Frederick A Masoudi; Mikhail Kosiborod
Journal:  Diabetes Care       Date:  2012-03-12       Impact factor: 19.112

5.  The reliability of in-hospital diagnoses of diabetes mellitus in the setting of an acute myocardial infarction.

Authors:  Suzanne V Arnold; Kasia J Lipska; Silvio E Inzucchi; Yan Li; Philip G Jones; Darren K McGuire; Abhinav Goyal; Joshua M Stolker; Marcus Lind; John A Spertus; Mikhail Kosiborod
Journal:  BMJ Open Diabetes Res Care       Date:  2014-11-04

6.  Association of Glycemic Control Trajectory with Short-Term Mortality in Diabetes Patients with High Cardiovascular Risk: a Joint Latent Class Modeling Study.

Authors:  Sridharan Raghavan; Wenhui G Liu; Seth A Berkowitz; Anna E Barón; Mary E Plomondon; Thomas M Maddox; Jane E B Reusch; P Michael Ho; Liron Caplan
Journal:  J Gen Intern Med       Date:  2020-04-24       Impact factor: 5.128

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.